Importance of animal models in schizophrenia research

Australian and New Zealand Journal of Psychiatry

Volumn 39, Issue 7, 2005, Pages 550-557

  Van Den Buuse, M ^a   Garner, B ^a   Gogos, A ^a   Kusljic, S ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Amphetamine; Animal models; Genetically modified animals; Motor activity; Prepulse inhibition; Schizophrenia

Indexed keywords

AMPHETAMINE; GENE PRODUCT; NEUROTRANSMITTER; PSYCHOTROPIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; COGNITION; HYPERACTIVITY; LOCOMOTION; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; PSYCHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA;

ANIMALS; DISEASE MODELS, ANIMAL; LOCOMOTION; MICE; MICE, INBRED C57BL; NEURAL INHIBITION; PSYCHOTROPIC DRUGS; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 27744493193     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2005.01626.x     Document Type: Review

References (52)

1. Preuss TM. Taking the measure of diversity: comparative alternatives to the model-animal paradigm in cortical neuroscience. Brain, Behaviour and Evolution 2000; 55:287-299.
2. National Health and Medical Research Council, Commonwealth Scientifc and Industrial Research Organization, Australian Agricultural Council. Australian code of practice for the care and use of animals for scientific purposes. Canberra: Australian Government Publishing Service, 1990.
3. Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven, 1995:787-798.
4. Ellenbroek BA, Cools AR. Animal models with construct validity for schizophrenia. Behavioural Pharmacology 1990; 1:469-490.
5. Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behavioural Pharmacology 2000; 11:223-233.
6. Creese I, Iversen SD. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Research 1975; 83:419-436.
7. Kelly PH, Seviour PW, Iversen SD. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Research 1975; 94:507-522.
8. Drevets WC, Gautier C, Price JC et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry 2001; 49:81-96.
9. Martinez D, Slifstein M, Broft A et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. Journal of Cerebral Blood Flow and Metabolism 2003; 23:285-300.
10. Laruelle M, Abi-Dargham A, van Dyck CH et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America 1996; 93:9235-9240.
11. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological Psychiatry 1999; 46:56-72.
12. 2A receptor and the pathology of schizophrenia: a likely accomplice. Journal of Neurochemistry 2003; 85:1-13.
13. Kusljic S, Copolov DL, Van den Buuse M. Differential role of serotonergic projections arising from the dorsal and median raphe nuclei in locomotor hyperactivity and prepulse inhibition. Neuropsychopharmacology 2003; 28:2138-2147.
14. Kusljic S, Brosda J, Norman TR, Van den Buuse M. Serotonergic lesions of the median raphe nucleus enhance the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801) in rats. Brain Research 2005; (in press).
15. Harrison BJ, Olver JS, Norman TR, Nathan PJ. Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers. Human Psychopharmacology 2002; 17:293-297.
16. Kusljic S, Van den Buuse M. Functional dissociation between serotonergic pathways in dorsal and ventral hippocampus in psychotomimetic drug-induced locomotor hyperactivity and prepulse inhibition in rats. European Journal of Neuroscience 2004; 20:3424-3432.
17. Van den Buuse M, Garner B, Koch M. Neurodevelopmental models of schizophrenia: effects on prepulse inhibition. Current Molecular Medicine 2003; 3:459-471.
18. Maynard TM, Sikich L, Lieberman JA, LaMantia AS. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophrenia Bulletin 2001; 27:457-476.
19. Pantelis C, Yucel M, Wood SJ, McGorry PD, Velakoulis D. Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Autralian and New Zealand Journal of Psychiatry 2003; 37:399-406.
20. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001; 156:117-154.
21. Swerdlow NR, Geyer MA, Braff D. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001; 156:194-215.
22. Braff DL, Swerdlow NR, Geyer MA. Gating and habituation deficits in the schizophrenia disorders. Clinical Neuroscience 1995; 3:131-139.
23. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Molecular Psychiatry 2002; 7:1039-1053.
24. Van den Buuse M. Deficient prepulse inhibition of acoustic startle in Hooded-Wistar rats compared with Sprague-Dawley rats. Clinical and Experimental Pharmacology and Physiology 2003; 30:254-261.
25. Van den Buuse M. Prepulse inhibition of acoustic startle in spontaneously hypertensive rats. Behavioural Brain Research 2004; 154:331-337.
26. 1A receptor stimulation. European Neuropsychopharmacology 2004; 14:373-379.
27. 2A receptor. Behavioural Brain Research 2003; 143:201-207.
28. Gogos A, Van den Buuse M. Castration reduces the effect of serotonin-1A receptor stimulation on prepulse inhibition in rats. Behavioral Neuroscience 2003; 117:1407-1415.
29. Gogos A, Van den Buuse M. Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1A receptor agonist 8-OH-DPAT. Journal of Pharmacology and Experimental Therapeutics 2004; 309:267-274.
30. Castle D, Sham P, Murray R. Differences in distribution of ages of onset in males and females with schizophrenia. Schizophrenia Research 1998; 33:179-183.
31. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophrenia Research 1996; 20:247-252.
32. Kulkarni J, Riedel A, de Castella AR et al. Estrogen - A potential treatment for schizophrenia. Schizophrenia Research 2001; 48:137-144.
33. Sams-Dodd F. Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. Journal of Neuroscience Methods 1995; 59:157-167.
34. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Reviews in Neuroscience 1999; 10:59-90.
35. Morris RGM, Garrud P, Rawlins JNP, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982; 297:681-683.
36. Martin S, Jones ME, Simpson ER, Van den Buuse M. Impaired spatial working memory in aromatase-deficient (ArKO) mice. Neuroreport 2003; 14:1979-1982.
37. Schwabe K, Enkel T, Klein S, Schütte M, Koch M. Effects of neonatal lesions of the medial prefrontal cortex on adult rat behaviour. Behavioural Brain Research 2004; 153:21-34.
38. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry 2005; 10:40-68.
39. Bunney WE, Bunney BG, Vawter MP et al. Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders. American Journal of Psychiatry 2003; 160:657-666.
40. Swerdlow NR, Shoemaker JM, Platten A, Pitcher L, Goins J, Crain S. Heritable differences in the effects of amphetamine but not DOI on startle gating in albino and hooded outbred rat strains. Pharmacology, Biochemistry and Behavior 2003; 75:191-197.
41. Palmer AA, Breen LL, Flodman P, Conti LH, Spence MA, Printz MP. Identification of quantitative trait loci for prepulse inhibition in rats. Psychopharmacology (Berlin) 2003; 165:270-279.
42. Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends in Neuroscience 2001; 24:527-533.
43. In vivo Pharmacology Training Group. The fall and rise of in vivo pharmacology. Trends in Pharmacological Sciences 2002; 23:13-18.
44. Crawley JN, Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Hormones and Behaviour 1997; 31:197-211.
45. Kulkarni J. Women and schizophrenia: a review. Australian and New Zealand Journal of Psychiatry 1997; 31:46-56.
46. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proceedings of the National Academy of Sciences of the United States of America 1998; 95:6965-6970.
47. Britt KL, Drummond AE, Cox VA et al. An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene. Endocrinology 2000; 141:2614-2623.
48. Van den Buuse M, Simpson ER, Jones ME. Prepulse inhibition of acoustic startle in aromatase knock-out mice: effects of age and gender. Genes, Brain and Behavior 2003; 2:93-102.
49. Paylor R, Crawley JN. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology 1997; 132:169-180.
50. Crawley JN. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Research 1999; 835:18-26.
51. Rehn AE, Van den Buuse M, Copolov D, Briscoe T, Lambert G, Rees S. An animal model of chronic placental insufficiency: relevance to neurodevelopmental disorders including schizophrenia. Neuroscience 2004; 129:381-391.
52. Van den Buuse M, Eikelis N. Estrogen increases prepulse inhibition of acoustic startle in rats. European Journal of Pharmacology 2001; 425:33-41.